|Over a week ago|
new option listings on November 25th » 08:3011/2511/25/20
ABIO, AHCO, DMTK, DRIV, EDOC, EKSO, FAN, GP, KZIA, MSP, QLGN, ROOT, RVMD, TCON
New option listings for…
New option listings for November 25th include ARCA Biopharma (ABIO), AdaptHealth Corporation (Class A Stock) (AHCO), DermTech Inc (DMTK), Global X Autonomous and Electric Vehicles (DRIV), Direxion Daily Industrials Bull 3x Shares (DUSL), Global X E commerce ETF (EBIZ), Global X Telemedicine and Digital Health (EDOC), Ekso Bionics (EKSO), First Trust ISE Global Wind Energy Index Fund (FAN), Fidelity Low Volatility Factor ETF (FDLO), First Trust DJ Global Select Dividend Index Fund (FGD), GreenPower Motor Company Inc (GP), Direxion Daily South Korea Bull 3X Shares (KORU), Kazia Therapeutics Ltd (ADS) (KZIA), Datto Holding Corp (MSP), Qualigen Therapeutics Inc (QLGN), Root Inc (ROOT), Revolution Medicines Inc (RVMD), TRACON Pharmaceuticals (TCON), Direxion Daily Transportation Bull 3x Shares (TPOR), and WisdomTree Cloud Computing Fund (WCLD).
Turning Point price target raised to $130 from $120 at Oppenheimer » 05:0311/1311/13/20
Oppenheimer analyst Matthew Biegler raised the firm's price target on Turning Point Therapeutics to $130 from $120 and reiterates an Outperform rating on the shares following the company's Q3 results. The recent outperformance of Turning Point shares reflects investor enthusiasm for TPX-0022 and the company's macrocyclic discovery platform, which has now delivered "two potentially best-in-class TKIs for two very different targets," Biegler tells investors in a research note. He believes repotrectinib could receive accelerated approval by 2023.
Revolution Medicines reports Q3 EPS (42c), consensus (39c) » 07:3311/1211/12/20
Reports Q3 revenue…
Reports Q3 revenue $12.7M, consensus $14.24M. "Revolution Medicines is a leader in developing innovative medicines and treatment strategies on behalf of patients with RAS-addicted tumors. We are advancing a growing portfolio consisting of both direct RAS Inhibitors and RAS Companion Inhibitors designed to enable combination approaches, including RMC-4630 targeting SHP2, RMC-5552 targeting mTORC1, and inhibitors of SOS1," said Mark Goldsmith, CEO and chairman of Revolution Medicines. "In our RAS Companion Inhibitor portfolio, we continue to make important strides with RMC-4630, our clinical stage inhibitor of SHP2. We selected the recommended Phase 2 dose and schedule for both our monotherapy trial and the RMC-4630/cobimetinib combination arm of the RMC-4630-02 clinical trial, and each trial will further evaluate the appropriate RP2DS in expansion cohorts of molecularly selected patients. As anticipated, we recently dosed a first patient in a new combination study of RMC-4630 with the third-generation EGFR inhibitor, osimertinib. We also entered into a new clinical collaboration with AstraZeneca to study RMC-4630 in combination with an emerging asset targeting KRASG12C from AstraZeneca's portfolio. In addition, we accelerated growth of our RAS Inhibitor platform, which has produced a collection of potent, cell-active inhibitors of diverse oncogenic RAS variants responsible for the vast majority of RAS-addicted cancers. Previously, we demonstrated significant anti-tumor effects of a representative potent and oral inhibitor of KRASG12C. During the third quarter we confirmed the broad scope of our platform by demonstrating that representative KRASG12D inhibitors likewise induced tumor regressions in a preclinical model of human pancreatic cancer harboring the oncogenic KRASG12D mutation. We have advanced our KRASG12C/NRASG12C, KRASG12D, KRASG13C and KRASG12V inhibitor programs into lead optimization."
Cyclacel Pharmaceuticals reports Q3 EPS ($2.27), consensus (55c) » 16:1211/1111/11/20
As of September 30, cash…
As of September 30, cash and cash equivalents totaled $23.1M, compared to $11.9M as of December 31, 2019. The increase of $11.2M was primarily due to net proceeds of $18.3M from an equity financing in April, offset by net cash used in operating activities of $6.8M. There were no revenues for each of the three months ended September 30, 2020 and 2019.. "We continue to execute on our clinical development plan for fadraciclib and CYC140 in both liquid and solid cancers," said Spiro Rombotis, president and CEO. "The recent ENA presentation highlighted fadraciclib's oral bioavailability and deepening confirmed response as a single agent. Recent publications elaborated the mechanistic rationale for fadraciclib highlighting dual inhibition of CDK2 and CDK9 cancer pathways. We are encouraged by evidence of antileukemic activity in our studies of fadraciclib in combination with venetoclax in hematological malignancies, including CLL. Dr. Mark Kirschbaum, our newly appointed CMO, is reviewing our programs and streamlining our clinical work flows to progress our clinical strategy and improve efficiency. We are looking forward to reporting data from ongoing studies and outlining our clinical development plans for fadraciclib and CYC140 to drive shareholder value."
Syros Pharmaceuticals initiated with a Buy at Brookline » 07:5211/1011/10/20
Brookline analyst Leah…
Brookline analyst Leah Rush Cann initiated coverage of Syros Pharmaceuticals with a Buy rating and $19 price target. Success in the next five years is "highly dependent" on the FDA approval and launch of SY-1425 in hematologic cancers, the analyst noted. She anticipates data for SY-1425, the company's lead compound, at the 2020 ASH Meeting, Rush Cann tells investors.
Syros Pharmaceuticals reports Q3 EPS (43c), consensus (38c) » 16:0211/0511/05/20
Reports Q3 revenue $3.8M,…
Reports Q3 revenue $3.8M, consensus $2.5M
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital » 11:0911/0511/05/20
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah noted that Syros Pharmaceuticals announced abstracts for two oral presentations at the American Society of Hematology, or ASH, annual meeting that will showcase the efficacy of SY-1425 in combination with azacitidine in newly diagnosed and relapsed/recurring AML patients. The "impressive" 61% CR/CRi rate in new diagnosis patients held steady with what was previously reported, and the 15% CRi rate in r/r patients was "very encouraging," said Jallah, who believes that the combo could be competitive in both settings. The analyst, who said she "eagerly awaits additional updates at ASH," has a Buy rating and $20 price target on Syros shares.
Syros Pharmaceuticals management to meet virtually with JMP Securities » 04:5511/0511/05/20
Virtual Meeting to be…
Virtual Meeting to be held on November 6 hosted by JMP Securities.
Syros to present new data from Phase 2 SY-1425 trial at ASH meeting » 10:1811/0411/04/20
Syros Pharmaceuticals announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha agonist, at the 62nd American Society of Hematology Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-1425 in combination with azacitidine from a cohort of RARA-positive patients with relapsed or refractory acute myeloid leukemia and mature data on the combination in newly diagnosed unfit AML patients who are not suitable candidates for standard chemotherapy. In a separate poster presentation, Syros will present new data showing that the majority of RARA-positive patients have a disease phenotype associated with resistance to upfront treatment with venetoclax, further underscoring the potential of SY-1425 in combination to address an ongoing unmet need in newly diagnosed unfit AML patients.
Fly Intel: Top five analyst upgrades » 09:5411/0411/04/20
AMD, SPR, AMZN, BIDU, SYRS
Catch up on today's…
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Toshiya Hari saying the 17% pullback in the stock since the September highs presents a "compelling opportunity" to participate in AMD's "multi-year share gain and margin expansion story." 2. Spirit AeroSystems (SPR) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr saying Boeing's (BA) MAX is Spirit's largest and most profitable program, and its certification and initial deliveries appear likely by year-end. 3. Amazon.com (AMZN) upgraded to Buy from Hold at China Renaissance with analyst Ella Ji saying with its "industry-leading" user engagement, supply chain and logistics capacity, Amazon remains the best positioned e-commerce stock. 4. Baidu (BIDU) upgraded to Overweight from Equal Weight at Barclays with analyst Gregory Zhao saying the online marketing services and new artificial intelligence initiatives of Baidu Core are reaching an inflection point. 5. Syros Pharmaceuticals (SYRS) upgraded to Buy from Neutral at H.C. Wainwright with analyst Andrew Fein saying with the SY-1365 discontinuation behind the company, it is clear that Syros has been able to learn from what that asset provided and "make a strong decision to pursue the better of the two CDK7 inhibitors with SY-5609." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.